Candesartan — Discount Pricing

Other medications in Heart & Cardiovascular

• Cangrelor
• Captopril
• Carvedilol
• Chlorthalidone
• Cholestyramine
• Colesevelam
• Colestipol
• Colestipol (Lipid)

About Candesartan

Candesartan is a crucial medication often prescribed for managing high blood pressure and certain heart conditions. For many, the cost of essential prescription drugs can be a significant concern. TheDrugClub is dedicated to making vital medications like candesartan more accessible and affordable, helping you prioritize your health without the added financial strain.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Candesartan is approved for (FDA label)

Candesartan cilexetil tablets are an angiotensin II receptor blocker (ARB) indicated for: · Treatment of hypertension in adults and children 1 to < 17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions ( 1.1 ). · Treatment of heart failure (NYHA class II-IV); candesartan reduces cardiovascular death and heart failure hospitalization ( 1.2 ). 1.1 Hypertension Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to <17 years of age, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.

Source: Read the full FDA label on DailyMed. Label effective date: February 5, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Candesartan (FDA label)

WARNING: FETAL TOXICITY When pregnancy is detected, discontinue candesartan cilexetil tablets as soon as possible. [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )] Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions ( 5.1 ) and Use in Specific Populations ( 8.1 )]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. · When pregnancy is detected, discontinue candesartan cilexetil tablets as soon as possible. ( 5.1 , 8.1 ) · Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. ( 5.1 , 8.1 )

Source: FDA prescribing information (DailyMed). Set ID: 7eb297cb-ef1b-44e0-a49d-03727100579e. SPL document ID: eeef5a15-6a83-4012-aee3-486668b243a2. Label effective date: February 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Candesartan (FDA label)

4 mg are white to off-white, circular, biconvex, uncoated tablets, debossed with “ML 52” on one side and breakline on other side. 8 mg are light pink, circular, biconvex, uncoated tablets, debossed with “ML 53” on one side and breakline on other side. 16 mg are pink, circular, biconvex, uncoated tablets, debossed with “ML 54” on one side and breakline on other side. 32 mg are pink, circular, biconvex, uncoated tablets, debossed with “ML 55” on one side and breakline on other side. Tablets 4 mg, 8 mg, 16 mg, 32 mg ( 3 ).

Source: FDA prescribing information (DailyMed). Set ID: 7eb297cb-ef1b-44e0-a49d-03727100579e. SPL document ID: eeef5a15-6a83-4012-aee3-486668b243a2. Label effective date: February 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Candesartan (FDA label)

• Most common adverse reactions which caused adult patients to discontinue therapy for: ○ Hypertension were headache (0.6%) and dizziness (0.3%) ( 6.1 ). ○ Heart Failure were hypotension (4.1%) ( 5.3 ), abnormal renal function (6.3%) ( 5.4 ), and hyperkalemia (2.4%) ( 5.5 ). To report SUSPECTED ADVERSE REACTIONS, contact Macleods Pharma USA, Inc. at 1-888-943-3210 or 1-855-926-3384 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 7eb297cb-ef1b-44e0-a49d-03727100579e. SPL document ID: eeef5a15-6a83-4012-aee3-486668b243a2. Label effective date: February 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Candesartan (FDA label)

Candesartan cilexetil tablets are contraindicated in patients who are hypersensitive to candesartan. Do not co-administer aliskiren with candesartan cilexetil tablets in patients with diabetes [see Drug Interactions (7.4)]. Known hypersensitivity to product components ( 4 ). Do not co-administer aliskiren with candesartan cilexetil in patients with diabetes ( 4 ).

Source: FDA prescribing information (DailyMed). Set ID: 7eb297cb-ef1b-44e0-a49d-03727100579e. SPL document ID: eeef5a15-6a83-4012-aee3-486668b243a2. Label effective date: February 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Candesartan (FDA label)

• Observe for signs and symptoms of hypotension ( 5.3 ). • Monitor renal function ( 5.4 ) and potassium levels ( 5.5 ). 5.1 Fetal Toxicity Candesartan cilexetil tablets can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations. Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure and death. When pregnancy is detected, discontinue candesartan cilexetil as soon as possible [see Use in Specific Populations ( 8.1 )]. 5.2 Morbidity in Infants Children < 1 year of age must not receive candesartan cilexetil for hypertension.

Source: FDA prescribing information (DailyMed). Set ID: 7eb297cb-ef1b-44e0-a49d-03727100579e. SPL document ID: eeef5a15-6a83-4012-aee3-486668b243a2. Label effective date: February 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Candesartan (FDA label)

• Lithium: Increases in serum lithium concentrations and toxicity ( 7 ). • NSAIDs use may lead to increased risk of renal impairment and loss of antihypertensive effect ( 7 ) • Combined inhibition of the renin-angiotensin system: Increased risk of renal impairment, hypotension, and hyperkalemia ( 7 ) 7.1 Agents Increasing Serum Potassium Co-administration of candesartan cilexetil with potassium sparing diuretics, potassium supplements, potassium-containing salt substitutes or other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients. 7.2 Lithium Increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists, including candesartan cilexetil.

Source: FDA prescribing information (DailyMed). Set ID: 7eb297cb-ef1b-44e0-a49d-03727100579e. SPL document ID: eeef5a15-6a83-4012-aee3-486668b243a2. Label effective date: February 5, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.